Biofrontera reports successful outcomes from Phase 3 trial of Ameluz® PDT for Actinic …
Biofrontera, a pharmaceutical company, recently announced that it has signed a licensing agreement with Maruho Co., Ltd., a Japanese dermatology company. This agreement allows Maruho to commercialize and distribute Ameluz®, Biofrontera’s flagship drug, in Japan. Ameluz® is a prescription medicine used for photodynamic therapy (PDT) in the treatment of actinic keratosis (AK), a common skin condition caused by prolonged exposure to UV radiation.
The licensing agreement between Biofrontera and Maruho is a significant milestone for both companies. Maruho, a leading dermatology company in Japan, will benefit from the addition of Ameluz® to its portfolio of products. By commercializing and distributing Ameluz®, Maruho can expand its offerings in the field of dermatology and provide patients in Japan with a new treatment option for AK.
Biofrontera, on the other hand, stands to gain from the agreement through increased exposure and sales of Ameluz® in the Japanese market. By partnering with Maruho, a reputable company with a strong presence in Japan, Biofrontera can tap into a new market and reach a wider audience of patients in need of PDT treatment for AK.
In a statement regarding the licensing agreement, Hermann Lübbert, CEO of Biofrontera, expressed his excitement about the partnership with Maruho. He highlighted the potential for Ameluz® to make a positive impact on the lives of patients with AK in Japan. Lübbert emphasized Biofrontera’s commitment to advancing dermatology treatments and improving patient outcomes through innovative therapies like Ameluz®.
The Securities Litigation Reform Act of 1995, as amended, protects companies like Biofrontera from liability when making forward-looking statements. These statements, which include projections and forecasts about the company’s future performance, are not guarantees of future results. However, they provide investors and stakeholders with valuable insights into Biofrontera’s strategic direction and growth prospects.
Overall, the licensing agreement between Biofrontera and Maruho represents a promising opportunity for both companies. By leveraging their respective strengths and expertise in dermatology, they can work together to bring Ameluz® to patients in Japan and potentially improve the standard of care for AK. This partnership underscores the importance of collaboration in the pharmaceutical industry and the potential for innovative treatments like Ameluz® to make a meaningful difference in the lives of patients around the world.